For the quarter ending 2025-09-30, NXGL had $1,133K increase in cash & cash equivalents over the period. -$793K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Gain on investment in marketable securities | 0 | 0 |
| Net loss attributable to nexgel stockholders | -653 | -1,377 |
| Income (loss) attributable to non-controlling interest in joint venture | 6 | 59 |
| Depreciation and amortization | 113 | 225 |
| Net changes in operating lease assets and liabilities | 0 | 21 |
| Changes in fair value of warrant liability and warrant modification expense | -8 | -104 |
| Accounts receivable, net | 86 | -180 |
| Inventory | 198 | 70 |
| Prepaid expenses and other assets | 23 | 240 |
| Accounts payable | -31 | 65 |
| Accounts payable related party | -26 | -84 |
| Accrued expenses and other current liabilities | -4 | 224 |
| Deferred revenue | 0 | 1 |
| Partnership accrued advance | -80 | - |
| Share-based compensation | 205 | 293 |
| Net cash used in operating activities | -785 | -807 |
| Proceeds from sales of marketable securities | 0 | 0 |
| Net cash paid for asset acquisition | 0 | 0 |
| Capital expenditures | 8 | 20 |
| Net cash used in investing activities | -8 | -20 |
| Proceeds from margin line of credit | 0 | - |
| Investment by joint venture partner | 0 | 0 |
| Change in contingent consideration liability | 0 | - |
| Proceeds from stada (note 17) | 1,000 | - |
| Proceeds from equity offerings | 1,055 | 0 |
| Stock issuance costs | 92 | - |
| Payment of contingent consideration liability | 0 | 178 |
| Principal payment on financing lease liability | 14 | 29 |
| Principal payments of notes payable | 23 | 48 |
| Net cash provided by financing activities | 1,926 | -255 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 1,133 | -1,082 |
| Cash and cash equivalents at beginning of period | 1,807 | - |
| Cash and cash equivalents at end of period | 1,858 | - |
NEXGEL, INC. (NXGL)
NEXGEL, INC. (NXGL)